PR Newswire Clinical TrialsOriginal article
Phanes Therapeutics announces first patient with colorectal cancer (CRC) dosed in clinical study of spevatamig
Trial StartspevatamigPositive
AI Analysis
Summary
Phanes Therapeutics announced the first patient has been dosed in a clinical study of spevatamig for colorectal cancer treatment. The company is a clinical-stage biotech focused on immuno-oncology drug discovery and development.
Clinical Trial Data
Patients
1
Outcome Details
First patient dosed in clinical study
Importance:5/10
Sentiment:
0.50
immuno-oncologycolorectal cancerclinical trialfirst patient dosed
Read the original article
Published by PR Newswire Clinical Trials on October 14, 2026 5:22 PM